Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10966MR)

This product GTTS-WQ10966MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10966MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9090MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ239MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ12023MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ722MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ7018MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ3734MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ4909MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ1544MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW